Allogene Therapeutics is testing a first-line consolidation strategy in LBCL, aiming to identify and reduce relapse risk after initial treatment through its ALP

Allogene Therapeutics is testing a first-line consolidation strategy in LBCL, aiming to identify and reduce relapse risk after initial treatment through its ALPHA3 trial. The effort adds to momentum for cema-cel, which has FDA RMAT and Fast Track status.